We discuss updated safety results from the ELEVATE R/R study, which is the first study comparing acalabrutinib with ibrutinib head-to-head in patients with relapsed/refractory CLL.
At the American Society of Clinical Oncology (ASCO) Annual Meeting in 2022, we received the four-year follow-up data update on the ASCEND trial.
This trial compared acalabrutinib (acala) to the treating doctor’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia.
The FDA has signed off on a new tablet formulation for acalabrutinib (Calquence) for patients with CLL / SLL, according to a news release from drugmaker AstraZeneca. It is now possible to take acalabrutinib along with stomach acid-reducing agents.
Acalabrutinib (A) and ibrutinib (I) are both highly effective Bruton tyrosine kinase (BTK) inhibitors approved for the treatment of chronic lymphocytic leukemia (CLL) and given as continuous treatments until disease progression or unacceptable toxicity.
Ask the Doctor Question: I have to start my first therapy soon and living in Germany. First diagnosis in 2015 and until now, watch and wait. ighv mutated, trisomie12, birc3 mutation.
Ask the Pharmacist Question: What steps can I take to improve absorption of acalabrutinib. I had a total gastrectomy in 1974 and a Roux en Y in 2005, so my compromised
Ask the Pharmacist Question: Are there any side effects of dysphasia or esophageal spasm when taking acalabrutinib? I began this treatment 9/1/2021 and these effects began 2-3 weeks ago. I have
This video was recorded at the 62nd Annual Meeting of the American Society of Hematology, held virtually in December 2020. Dr. Davids specializes in CLL and serves on the CLL Society’s Medical Advisory Board.
In this interview, our own Dr. Brian Koffman spoke with Dr. Neil Kay, a Professor of Medicine and a hematologist at Mayo Clinic, and Dr. Sameer Parikh, a hematologist, an oncologist at the Mayo Clinic in Rochester, MN. They discussed why early-stage patients usually do not receive treatment and how that paradigm may be changing with the availability of new targeted therapies and better prognostic markers.
